Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Janice McAlister

Nurse Practitioner Atlanta, GA Nurse Practitioner

NPI 1164566253 CMS profile 10677898

275 Collier Rd Nw, Suite 500, Atlanta, GA 30309

Open in the dashboard

General payments

$220,678

663 records reported · program years 2021–2025

Research payments

$4,145

Paid to them · 1 record reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$20,656 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Janice McAlister of Atlanta, GA is reported in the CMS Open Payments database as having received $220,678 across 663 general payments and $4,145 in research payments paid to them. Separately, studies naming them as principal investigator received $20,656 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,195 104
2024 General $19,486 100
2024 Research $4,145 1
2023 General $37,103 123
2022 General $88,724 233
2021 General $49,170 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janice McAlister
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Janice McAlister were reported at $26,195. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Janice McAlister Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $49,170 $135 $40–$426 $132
2022 $88,724 $152 $48–$470 $149
2023 $37,103 $166 $54–$529 $160
2024 $19,486 $173 $55–$556 $164
2025 $26,195 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $174,888 415 payments
  2. Esperion Therapeutics, Inc. $31,074 70 payments
  3. Novartis Pharmaceuticals Corporation $8,602 126 payments
  4. Merck Sharp & Dohme Corporation $4,081 11 payments
  5. Chiesi USA, Inc. $606 3 payments
  6. HeartFlow, Inc. $199 2 payments
  7. Inspire Medical Systems, Inc. $183 2 payments
  8. Regeneron Pharmaceuticals, Inc. $176 2 payments
  9. Allergan Inc. $168 8 payments
  10. Biotronik Inc. $135 1 payment
  11. Other $567 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $145,805 126 payments
  2. Travel and Lodging $46,909 191 payments
  3. Food and Beverage $15,618 336 payments
  4. Consulting Fee $11,727 7 payments
  5. Honoraria $600 2 payments
  6. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. Repatha Cardiology $153,761 360 payments
  2. NEXLETOL $31,074 70 payments
  3. NEXLIZET $30,770 60 payments
  4. REPATHA Cardiovascular $16,269 37 payments
  5. LEQVIO Cardiology/Vascular Diseases $6,342 100 payments
  6. LEQVIO Cardiovascular $2,062 20 payments
  7. JUXTAPID $606 3 payments
  8. ENTRESTO Cardiology/Vascular Diseases $371 29 payments
  9. ENTRESTO Cardiovascular $254 19 payments
  10. EVKEEZA $218 4 payments
  11. Other $1,593 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $4,145 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

5,180

Median for Nurse Practitioner: 389

Drug cost

$3,923,095

Median for Nurse Practitioner: $21,885

Branded share of claims

53.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 1,881 $2,501,183
Evkeeza Evinacumab-Dgnb Brand 13 $630,040
Praluent Pen Alirocumab Brand 358 $445,770
Nexletol Bempedoic Acid Brand 146 $78,025
Nexlizet Bempedoic Acid/Ezetimibe Brand 89 $57,517
Vascepa Icosapent Ethyl Brand 80 $49,781
Eliquis Apixaban Brand 20 $32,708
Repatha Syringe Evolocumab Brand 23 $32,603
Entresto Sacubitril/Valsartan Brand 11 $21,996
Ezetimibe Generic 813 $19,302

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$1,875,252

Of which drugs: $1,762,913

Medicare patients

785

Average age 75

Services billed

189,405

384 women, 401 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Arthritis 49%
Diabetes 24%
Chronic kidney disease 24%
Atrial fibrillation 22%
Heart failure 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 357 186,588 $1,762,921

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $17,718
$17,718 1,904 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $849
$849 — 186,588
FARXIGA
  • AstraZeneca Pharmaceuticals LP $122
$122 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $77
$77 146 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $68
$68 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record